Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Rocket Pharma Q&A: efficacy of gene therapy in Fanconi anaemia

Due to the need for chemotherapy and the risks caused by allogeneic stem cell transplants in Fanconi anaemia patients, Rocket Pharma has developed gene therapy candidate RP-L102, which doesn’t need conditioning and corrects the gene mutation underlying Fanconi. Rocket CEO Guarav Shah explains RP-L102’s mechanism of action, as well as how the company is working to improve its cell culturing methods and overcome continuing risks of head and neck cancer.

Download our 2018 Technology, Media & Telecoms Predictions worth over $5,000 for free

Close
Close
Close

Go Top